Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
GLP-1 medications changed obesity treatment, but appetite regulation involves more than one hormonal signal. Cagrilintide is a long-acting analogue of amylin, a pancreatic peptide released alongside insulin that helps regulate satiety, gastric emptying, and post-meal glucagon signaling.
In this episode of Peptides Explained, John Garrett breaks down what cagrilintide is, how it differs from GLP-1 receptor agonists, what standalone phase 2 data show, and what the phase 3 CagriSema trials tell us about combining cagrilintide with semaglutide.
We also examine the REDEFINE 4 comparison with tirzepatide, common gastrointestinal adverse effects, unresolved questions about long-term outcomes and lean mass, and why online research products should not be treated as equivalent to the pharmaceutical trial material.
Cagrilintide remains investigational and is not currently an FDA-approved treatment. This content is educational and is not medical advice.
Peptides Explained is an affiliate partner with Offline Peptides. Research-use products are not approved medications and are not intended for human use.
Visit: PeptidesExplained.info/OfflinePeptides
For information on Compounded Peptides through Premier Pharmacy visit Peptide Solutions and submit a request for more information
Visit: Peptide-Solutions.info and submit a request for more information
Send a two- to three-minute N=1 video to john@peptidesexplained.info.
No links were found in this episode’s notes.